Advanced

Measuring cancer prevalence in Europe: the EUROPREVAL project

Capocaccia, R; Colonna, M; Corazziari, I; De Angelis, R; Francisci, S; Micheli, A; Mugno, E; EUROPREVAL Working Group:, the; Möller, Torgil LU and Anderson, Harald LU , et al. (2002) In Annals of Oncology 13(6). p.831-839
Abstract
Cancer prevalence is the proportion of individuals in a population who at some stage during their lifetime have been diagnosed with cancer, irrespective of the date of diagnosis. Cancer prevalence statistics have generally been provided by a limited number of well established cancer registries that have been in existence for several decades. The advent of systematic follow-up of life status of incident cases and the availability of new statistical methodologies, now makes it possible for registries established during the 1970s or 1980s to provide prevalence data. The main problems encountered in the estimation of prevalence are the inclusion of: (i) cases lost to follow-up; (ii) cases known only from their death certificate; (iii) cases... (More)
Cancer prevalence is the proportion of individuals in a population who at some stage during their lifetime have been diagnosed with cancer, irrespective of the date of diagnosis. Cancer prevalence statistics have generally been provided by a limited number of well established cancer registries that have been in existence for several decades. The advent of systematic follow-up of life status of incident cases and the availability of new statistical methodologies, now makes it possible for registries established during the 1970s or 1980s to provide prevalence data. The main problems encountered in the estimation of prevalence are the inclusion of: (i) cases lost to follow-up; (ii) cases known only from their death certificate; (iii) cases diagnosed before the start of registration; and (iv) the treatment of multiple tumours and migrations. The main aim of this paper was to review these problems and discuss, through the experience gained with EUROPREVAL, how they can be overcome. A method is presented for the calculation of prevalence of all cancers combined in the populations covered by the 45 cancer registries participating in EUROPREVAL. Prevalence of cancer is estimated to be 2% on average, with the highest values (3%) in Sweden and the lowest in Eastern Europe, with a minimum of approximately 1% in Poland. (Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
prevalence, methods, epidemiology, Europe, tumours
in
Annals of Oncology
volume
13
issue
6
pages
831 - 839
publisher
Oxford University Press
external identifiers
  • pmid:12123329
  • scopus:0035990051
ISSN
1569-8041
DOI
10.1093/annonc/mdf152
language
English
LU publication?
yes
id
a6be0423-4d78-4bde-ae47-22a3ee4509dd (old id 1123756)
date added to LUP
2008-09-01 13:40:39
date last changed
2017-10-01 04:50:53
@article{a6be0423-4d78-4bde-ae47-22a3ee4509dd,
  abstract     = {Cancer prevalence is the proportion of individuals in a population who at some stage during their lifetime have been diagnosed with cancer, irrespective of the date of diagnosis. Cancer prevalence statistics have generally been provided by a limited number of well established cancer registries that have been in existence for several decades. The advent of systematic follow-up of life status of incident cases and the availability of new statistical methodologies, now makes it possible for registries established during the 1970s or 1980s to provide prevalence data. The main problems encountered in the estimation of prevalence are the inclusion of: (i) cases lost to follow-up; (ii) cases known only from their death certificate; (iii) cases diagnosed before the start of registration; and (iv) the treatment of multiple tumours and migrations. The main aim of this paper was to review these problems and discuss, through the experience gained with EUROPREVAL, how they can be overcome. A method is presented for the calculation of prevalence of all cancers combined in the populations covered by the 45 cancer registries participating in EUROPREVAL. Prevalence of cancer is estimated to be 2% on average, with the highest values (3%) in Sweden and the lowest in Eastern Europe, with a minimum of approximately 1% in Poland.},
  author       = {Capocaccia, R and Colonna, M and Corazziari, I and De Angelis, R and Francisci, S and Micheli, A and Mugno, E and EUROPREVAL Working Group:, the and Möller, Torgil and Anderson, Harald and al, et},
  issn         = {1569-8041},
  keyword      = {prevalence,methods,epidemiology,Europe,tumours},
  language     = {eng},
  number       = {6},
  pages        = {831--839},
  publisher    = {Oxford University Press},
  series       = {Annals of Oncology},
  title        = {Measuring cancer prevalence in Europe: the EUROPREVAL project},
  url          = {http://dx.doi.org/10.1093/annonc/mdf152},
  volume       = {13},
  year         = {2002},
}